Patents Represented by Attorney, Agent or Law Firm Kristina Bieker-Brady
  • Patent number: 7435419
    Abstract: Disclosed herein are methods for diagnosing pre-eclampsia and eclampsia or a propensity to develop pre-eclampsia or eclampsia by detecting the levels of placental growth factor in a subject.
    Type: Grant
    Filed: December 21, 2004
    Date of Patent: October 14, 2008
    Assignee: Beth Israel Deaconess Medical Center
    Inventors: S. Ananth Karumanchi, Vikas P. Sukhatme
  • Patent number: 7427410
    Abstract: The present invention provides methods and apparatus for coating surfaces with specially designed thioethers and amphiphilic thioethers that reduce protein adsorption and/or cell adhesion. This reduction may be achieved, for example, by controlling the spacing or length of pendant chains or hydrophilic blocks in an amphiphilic thioether. Techniques for determining spacing include adsorbing the thioether from a solution or a colloidal suspension, or controlling the degree of polymerization of the thioether. Techniques for controlling the length of the pendant chains include controlling the degree of polymerization of the pendant chains. Multiblock copolymers of poly(propylene sulfide) and poly(ethylene glycol) (“PPS-PEG”) represent an exemplary family of amphiphilic thioethers. Methods for coating surfaces with amphiphilic thioethers are also provided.
    Type: Grant
    Filed: September 18, 2002
    Date of Patent: September 23, 2008
    Assignee: Ecole Polytechnique Federale de Lausanne (EPFL)
    Inventors: Jeffrey A. Hubbell, Jane P. Bearinger, Alessandro Napoli, Marcus Textor, Nicola Tirelli
  • Patent number: 6812376
    Abstract: Disclosed is a novel serotonin-gated anion channel that is permeable to chloride ions. Also disclosed are methods for the screening of therapeutics useful for treating serotonin-mediated cellular responses and conditions, as well as diagnostic methods for identifying such conditions.
    Type: Grant
    Filed: April 27, 2000
    Date of Patent: November 2, 2004
    Assignee: Massachusetts Institute of Technology
    Inventors: Rajesh Ranganathan, H. Robert Horvitz, Stephen C. Cannon
  • Patent number: 6797473
    Abstract: The invention features methods and reagents useful for the treatment of excessive or insufficient apoptosis in cells, and, particularly, in germ-line cells. The invention is useful in treating testicular cancers, cancers of germ-line cells, cancers in non-germ-line cell tissues, infertility (e.g., male infertility), and for birth control (e.g., male birth control).
    Type: Grant
    Filed: December 18, 2001
    Date of Patent: September 28, 2004
    Assignee: University of Ottawa
    Inventors: Robert G. Korneluk, Mark Lagacé
  • Patent number: 6787355
    Abstract: This invention relates to multipotent neural stem cells, purified from the peripheral nervous system of mammals, capable of differentiating into neural and non-neural cell types. These stem cells provide an accessible source for autologous transplantation into CNS, PNS, and other damaged tissues.
    Type: Grant
    Filed: September 25, 2000
    Date of Patent: September 7, 2004
    Assignee: McGill University
    Inventors: Freda D. Miller, Andrew Gloster, Jean Toma
  • Patent number: 6780973
    Abstract: Disclosed is substantially pure eotaxin DNA sequence and eotaxin polypeptide, and methods of using such DNA and polypeptide to direct chemotaxis of eosinophils. Methods are provided for the treatment diseases and disorders such as inflammation and tumorigenesis.
    Type: Grant
    Filed: March 2, 2000
    Date of Patent: August 24, 2004
    Assignees: President and Fellows of Harvard College, The General Hospital Corporation
    Inventors: Andrew D. Luster, Philip Leder, Marc Rothenberg, Eduardo Garcia
  • Patent number: 6730662
    Abstract: The invention features E4orf4-encoding nucleic acids, pharmaceutical compositions and expression vectors containing the same, and methods for their use. E4orf4-encoding nucleic acids include (i) nucleic acids capable of hybridizing at high stringency to the complement of the nucleic acid encoding Ad2E4orf4, and (ii) nucleic acids having 50% or greater nucleotide sequence identity to the nucleotide sequence of Ad2E4orf4, so long as the nucleic acids encode a polypeptide capable of inducing apoptosis.
    Type: Grant
    Filed: June 7, 1999
    Date of Patent: May 4, 2004
    Assignee: McGill University
    Inventors: Philip E. Branton, Gordon C. Shore, Jose G. Teodoro, Richard C. Marcelius, Josee N. Lavoie
  • Patent number: 6723893
    Abstract: Disclosed is the family of genes responsible for the neurodegenerative diseases, particularly Amyotrophic Lateral Sclerosis. Methods and compounds for the diagnosis, prevention, and therapy of the disease are also disclosed.
    Type: Grant
    Filed: February 28, 1994
    Date of Patent: April 20, 2004
    Assignees: Massachusetts Institute of Technology, The General Hospital Corporation, Inc.
    Inventors: Robert Brown, H. Robert Horvitz, Daniel R. Rosen
  • Patent number: 6706766
    Abstract: The invention features methods for increasing cell death. The invention also features compounds used to increase cell death. The invention further features methods for identifying compounds that increase cell death.
    Type: Grant
    Filed: July 16, 2002
    Date of Patent: March 16, 2004
    Assignee: President and Fellows of Harvard College
    Inventors: Junying Yuan, Alexei Degterev, Timothy J. Mitchison
  • Patent number: 6703037
    Abstract: A method for delivering a biologically active substance including the steps of: (a) combining said biologically active substance with a macromer; (b) forming a mixture of the combination formed in step (a); (c) polymerizing said mixture to form articles; and (d) administering said articles, or a portion thereof, to a mammal, where step (c) takes place in the absence of a polymerizable monovinyl monomer, is disclosed.
    Type: Grant
    Filed: October 12, 2000
    Date of Patent: March 9, 2004
    Assignee: Pelias Technologies, Inc.
    Inventors: Jeffrey A. Hubbell, Mark T. Kieras, Eyal S. Ron, Stephen C. Rowe
  • Patent number: 6703197
    Abstract: The invention features a method for detecting an increased likelihood of hyperhomocysteinemia and, in turn, an increased or decreased likelihood of neural tube defects or cardiovascular disease. The invention also features therapeutic methods for reducing the risk of neural tube defects, colon cancers and related cancers. Also provided are the sequences of the human methionine synthase gene and protein and compounds and kits for performing the methods of the invention.
    Type: Grant
    Filed: November 26, 1997
    Date of Patent: March 9, 2004
    Assignee: Martinex R&D, Inc.
    Inventors: Roy A. Gravel, Rima Rozen, Daniel LeClerc, Philippe Goyette, Eric Campeau
  • Patent number: 6699486
    Abstract: Disclosed herein are methods for the treatment or prevention of photoaging or skin cancer in a patient. These methods include administering a compound that inhibits a component of the kallikrein inflammatory pathway in an amount sufficient to reduce one or more symptoms of photoaging or skin cancer.
    Type: Grant
    Filed: November 17, 2000
    Date of Patent: March 2, 2004
    Assignee: Bolla Corporation
    Inventor: John D. Bolla
  • Patent number: 6699504
    Abstract: The invention features articles for delivery of a biologically active substance, methods for making such articles, and methods for treating an animal using the articles.
    Type: Grant
    Filed: January 29, 2001
    Date of Patent: March 2, 2004
    Assignee: Pelias Technologies, Inc.
    Inventors: Stephen C. Rowe, Kalvin Yim, Beadle P. Retnarajan, Jeffrey A. Hubbell, Durga Annavajula
  • Patent number: 6689608
    Abstract: Polymeric materials are used,to make a pliable, non-toxic, injectable porous template for vascular ingrowth. The pore size, usually between approximately 100 and 300 microns, allows vascular and connective tissue ingrowth throughout approximately 10 to 90% of the matrix following implantation, and the injection of cells uniformly throughout the implanted matrix without damage to the cells or patient. The introduced cells attach to the connective tissue within the matrix and are fed by the blood vessels. The preferred material for forming the matrix or support structure is a biocompatible synthetic polymer which degrades in a controlled manner by hydrolysis into harmless metabolites, for example, polyglycolic acid, polylactic acid, polyorthoester, polyanhydride, or copolymers thereof. The rate of tissue ingrowth increases as the porosity and/or the pore size of the implanted devices increases.
    Type: Grant
    Filed: September 26, 2000
    Date of Patent: February 10, 2004
    Assignee: Massachusetts Institute of Technology
    Inventors: Antonios G. Mikos, Robert S. Langer, Joseph P. Vacanti, Linda G. Griffith, Georgios Sarakinos
  • Patent number: 6689562
    Abstract: Disclosed is substantially pure DNA encoding mammalian IAP polypeptides; substantially pure polypeptides; and methods of using such DNA to express the IAP polypeptides in cells and animals to inhibit apoptosis. Also disclosed are conserved regions characteristic of the IAP family and primers and probes for the identification and isolation of additional IAP genes. In addition, methods for treating diseases and disorders involving apoptosis are provided.
    Type: Grant
    Filed: December 1, 1998
    Date of Patent: February 10, 2004
    Assignee: AEGERA Therapeutics Inc.
    Inventors: Robert G. Korneluk, Alexander E. MacKenzie, Stephen Baird, Peter Liston
  • Patent number: 6677374
    Abstract: Compounds and methods for mitigating neurodegeneration, effecting neuroprotection and/or effecting cognition enhancement in a subject are described. Neurological or cognitive conditions are treated by administering to a subject an effective amount of a therapeutic compound comprising a nitrate ester, or a pharmaceutically acceptable salt or ester thereof.
    Type: Grant
    Filed: March 29, 2002
    Date of Patent: January 13, 2004
    Assignee: Queen's University at Kingston
    Inventors: Gregory R. J. Thatcher, Brian M. Bennett, James N. Reynolds, Roland J. Boegman, Khem Jhamandas
  • Patent number: 6673586
    Abstract: The present invention features a novel p21-activated kinase that interacts with steroid hormone receptors, the steroid hormone receptor interacting p21-activated kinase (PAKSI). In general, the invention provides methods of inhibiting hormone related cancers. More particularly, the present invention relates to inhibiting prostate cancer and breast cancer. The present invention further provides methods of activating the therapeutic effects of steroid hormone receptors, particularly the estrogen receptor. Alternatively, the present invention provides methods of diagnosing steroid hormone receptor-related diseases.
    Type: Grant
    Filed: January 19, 2001
    Date of Patent: January 6, 2004
    Assignee: Beth Israel Deaconess Medical Center
    Inventor: Steven Balk
  • Patent number: 6673917
    Abstract: The present invention feature antisense IAP nucleic acids and other negative regulators of the IAP anti-apoptotic pathway, and methods for using them to enhance apoptosis.
    Type: Grant
    Filed: September 28, 2000
    Date of Patent: January 6, 2004
    Assignee: University of Ottawa
    Inventors: Robert G. Korneluk, Eric LaCasse, Stephen Baird, Martin Holcik, Sean Young
  • Patent number: 6673915
    Abstract: Substantially pure nucleic acid molecules encoding the monocyte chemotactic proteins MCP-4 and MCP-5. These molecules and the polypeptides they encode are useful in treating diseases or conditions that: (1) are exacerbated by a local immune response, (2) would benefit from a local immune response, or (3) are caused by infectious agents that gain entry to mammalian cells via the chemokine receptors bound by MCP-4 or MCP-5.
    Type: Grant
    Filed: April 7, 2000
    Date of Patent: January 6, 2004
    Assignee: General Hospital Corporation
    Inventors: Andrew D. Luster, Eduardo A. Garcia-Zepeda, Mindy N. Sarafi
  • Patent number: 6656704
    Abstract: Disclosed is substantially pure DNA encoding mammalian IAP polypeptides; substantially pure polypeptides; and methods of using such DNA to express the IAP polypeptides in cells and animals to inhibit apoptosis. Also disclosed are conserved regions characteristic of the IAP family and primers and probes for the identification and isolation of additional IAP genes. In addition, methods for treating diseases and disorders involving apoptosis are provided.
    Type: Grant
    Filed: September 14, 1998
    Date of Patent: December 2, 2003
    Assignee: Aegera Therapeutics Inc.
    Inventors: Robert G. Korneluk, Alexander E. MacKenzie, Stephen Baird, Peter Liston